532649 Stock Overview
Manufactures and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nectar Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹33.32 |
| 52 Week High | ₹56.39 |
| 52 Week Low | ₹26.20 |
| Beta | 1.03 |
| 11 Month Change | 0.03% |
| 3 Month Change | -18.21% |
| 1 Year Change | 9.68% |
| 33 Year Change | 40.00% |
| 5 Year Change | 165.71% |
| Change since IPO | 28.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532649 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.4% | 2.3% | 2.4% |
| 1Y | 9.7% | 43.8% | 29.5% |
Return vs Industry: 532649 underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: 532649 underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| 532649 volatility | |
|---|---|
| 532649 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532649's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 532649's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,686 | Amit Chadah | www.neclife.com |
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.
Nectar Lifesciences Limited Fundamentals Summary
| 532649 fundamental statistics | |
|---|---|
| Market cap | ₹7.39b |
| Earnings (TTM) | ₹107.27m |
| Revenue (TTM) | ₹16.79b |
68.9x
P/E Ratio0.4x
P/S RatioIs 532649 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532649 income statement (TTM) | |
|---|---|
| Revenue | ₹16.79b |
| Cost of Revenue | ₹11.69b |
| Gross Profit | ₹5.11b |
| Other Expenses | ₹5.00b |
| Earnings | ₹107.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 30.40% |
| Net Profit Margin | 0.64% |
| Debt/Equity Ratio | 58.4% |
How did 532649 perform over the long term?
See historical performance and comparison